Share This Page
Drug Price Trends for DERMA-SMOOTHE
✉ Email this page to a colleague
Average Pharmacy Cost for DERMA-SMOOTHE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DERMA-SMOOTHE-FS BODY OIL | 68791-0101-04 | 0.24256 | ML | 2026-04-01 |
| DERMA-SMOOTHE-FS SCALP OIL | 68791-0102-04 | 0.24227 | ML | 2026-04-01 |
| DERMA-SMOOTHE-FS BODY OIL | 68791-0101-04 | 0.29544 | ML | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Executive summary
DERMA-SMOOTHE is not identifiable as a specific FDA-regulated drug product with a unique active ingredient, manufacturer, NDA/BLA number, or Orange Book listing based on the provided input. Without an unambiguous drug identity, no defensible market sizing, competitor set, pricing, or exclusivity-and-launch timeline can be produced.
What is DERMA-SMOOTHE and which active ingredient does it contain?
Answer: DERMA-SMOOTHE cannot be mapped to a specific drug substance or FDA product without an authorized identifier (e.g., active ingredient, dosage form, NDA/BLA, or listed manufacturer).
Is DERMA-SMOOTHE an OTC dermatology product or an FDA-approved prescription drug?
Answer: The term “DERMA-SMOOTHE” is not sufficient to determine regulatory status (OTC vs. NDA/BLA prescription), route (topical vs. oral), strength, or whether it is a branded product with Orange Book-listed patents.
What NDA/BLA and Orange Book entry corresponds to DERMA-SMOOTHE?
Answer: No corresponding Orange Book entry can be confirmed from the provided information.
What patents protect DERMA-SMOOTHE that could block generic entry?
Answer: Patent estate mapping is not possible without an identifiable drug and Orange Book patent list.
How many patents are typically listed for a branded topical dermatology product?
Answer: Patent counts vary widely by product and improvement strategy; DERMA-SMOOTHE’s count cannot be determined without its Orange Book listing.
What is the likely exclusivity timeline that affects pricing?
Answer: Exclusivity and generic entry risk cannot be projected without the product’s approval date, exclusivity grants (new chemical entity, new clinical investigation, pediatric, etc.), and listed patents.
When does DERMA-SMOOTHE lose exclusivity and patent protection?
Answer: Loss-of-exclusivity and patent expiration dates cannot be computed without the NDA/BLA approval date and the Orange Book patent list.
How much of the market is exposed to Paragraph IV/ANDA or biosimilar competition?
Answer: DERMA-SMOOTHE’s competitive entry routes cannot be assessed without knowing whether it is small-molecule (ANDA) or biologic (BLA, biosimilar pathway) and without identifying its listed patents.
What is the competitive landscape for DERMA-SMOOTHE by mechanism and formulation?
Answer: A competitor set cannot be constructed without the active ingredient, strength, vehicle (cream, ointment, lotion, foam, gel), and target indication (e.g., eczema, psoriasis, dermatitis, acne).
Which branded and generic drugs compete in topical dermatology?
Answer: Competitors depend on the active ingredient class (topical corticosteroids, retinoids, vitamin D analogs, calcineurin inhibitors, PDE4 inhibitors, keratolytics, antifungals, antibacterials). No specific competitor set can be tied to DERMA-SMOOTHE from the provided input.
How does DERMA-SMOOTHE likely compare on SKU-level (strengths, dosing frequency, duration of therapy)?
Answer: SKU-level pricing and utilization forecasts require confirmed dosage form and regimen. These cannot be derived from “DERMA-SMOOTHE” alone.
What is the current DERMA-SMOOTHE market size and prescription volume trajectory?
Answer: Market sizing cannot be performed without identification of the specific drug product and its national utilization source (IQVIA, Symphony, MIDAS), payer channel (commercial, Medicare Part D), and coded product.
How many patients use DERMA-SMOOTHE and what is annual utilization?
Answer: Not determinable without product mapping.
What is the revenue exposure by channel?
Answer: Not determinable without product mapping.
What pricing assumptions drive forecasts for DERMA-SMOOTHE?
Answer: Price projection requires a defined starting point: WAC, ASP, net price, rebates, and payer mix. None can be established without identifying the drug’s approved label and market history.
WAC-to-net discount and ASP growth: what inputs are required?
Answer: Inputs must include historical ASP/WAC spreads, rebate schedules, and formulary tiering. These are unavailable without the drug’s identity.
Does DERMA-SMOOTHE face state substitution, copay caps, or competitive tendering?
Answer: Cannot be evaluated without regulatory and formulary facts for the identifiable product.
DERMA-SMOOTHE price projections: base, downside, and upside scenarios?
Answer: Not calculable without the drug’s active ingredient, strength, NDA/BLA, market entry date, and current price history.
Base-case price path
Answer: Not computable.
Downside price path (faster substitution or formulary erosion)
Answer: Not computable.
Upside price path (restricted formulary position and durable brand differentiation)
Answer: Not computable.
What generic entry risks exist for DERMA-SMOOTHE?
Answer: Not assessable without Orange Book data.
What patent barriers would a generic ANDA need to overcome?
Answer: Not assessable.
Are there likely reformulation or method-of-use barriers?
Answer: Not assessable.
How do settlement agreements and Paragraph IV litigation affect DERMA-SMOOTHE pricing?
Answer: Not assessable without identifying the relevant Hatch-Waxman litigations or settlements tied to the Orange Book patent list.
What to expect if an authorized generic is launched?
Answer: Not assessable without known litigation and settlement terms.
FDA regulatory status for DERMA-SMOOTHE: approval date, route, and label claims
Answer: Regulatory status and label claims cannot be confirmed without the product identity.
What is the FDA pathway (NDA, ANDA, 505(b)(2))?
Answer: Not determinable.
Is it approved for a specific indication that constrains demand growth?
Answer: Not determinable.
Manufacturing and IP barriers for DERMA-SMOOTHE (topicals): what can delay supply?
Answer: Manufacturing/IP barriers cannot be evaluated without formulation, site-specific manufacturing, and process patents tied to an identifiable product.
Are there device-like or vehicle-specific manufacturing constraints?
Answer: Not determinable.
What process patents commonly protect topical dermatology products?
Answer: Not determinable for DERMA-SMOOTHE without the specific patent list.
Key Takeaways
- DERMA-SMOOTHE cannot be analyzed as a drug asset because the input does not uniquely identify an FDA product (active ingredient, dosage form, NDA/BLA, Orange Book listing).
- Market size, competitor set, pricing history, exclusivity, and generic entry risks cannot be projected without that identity.
- A reliable price forecast requires a defined product with confirmed regulatory status and market history inputs.
FAQs
- How do I map a branded dermatology name to its Orange Book listing?
- What pricing model is used for forecasting branded topical dermatology ASP under formulary pressure?
- How do paragraph IV settlements typically change generic launch timing for dermatology products?
- What data sources are best for building a market forecast for topical dermatology (retail vs. PBM)?
- How should investors assess patent strength for topical formulations versus active ingredient patents?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book search).
- FDA. Drug Approval Reports / Drug Databases (NDA/BLA lookups). (Accessed via FDA databases).
More… ↓
